was licensed for use in adults aged 鈮18 years by the US Food and Drug Administration (FDA). Objective To describe reports to the Vaccine Adverse Event Reporting System (VAERS) after administration of the 20-valent pneumococcal conjugate vaccine in adults. Methods We searched the VAERS for ...
pneumococcal conjugate vaccinepneumococcal diseaseBackground:V114 (15-valent pneumococcal conjugate vaccine [PCV15]) and a 20-valent PCV (PCV20) are approved for adults (鈮 18years) in the United States. We present methodologies to indirectly compare immune responses to V114 versus PCV20. ...
V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) specifically designed for adults. It includes eight unique serotypes (15A, 15C [generated from deOAc-15B], 16F, 23A, 23B, 24F, 31 and 35B) not covered by any currently licensed pneumococcal vaccine (Figure 1). This ...
Higher-valent vaccines (which provide coverage for a greater number of disease-causing serotypes) have recently received European Commission approval for use in adults and children. This study examined costs and health benefits associated with the 20-valent pneumococcal conjugate vaccine (PCV20) under...
pneumococcal conjugate vaccine (PCV); PCV20; PCV15; invasive pneumococcal disease (IPD); cost-effectiveness; vaccine effectiveness; vaccine1. Introduction Streptococcus pneumoniae is a major cause of illness and death among children and adults, with vaccination being the key method for preventing ...